| III-33 Alan Faraj Phase-3 dose selection of marzeptacog alfa (activated) in children enabled by model-informed drug development techniques |
| III-33 Alan Faraj Phase-3 dose selection of marzeptacog alfa (activated) in children enabled by model-informed drug development techniques |